Andecaliximab

Andecaliximab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	1518996-49-0
PubChem
DrugBank
ChemSpider	none
KEGG	D11262

Andecaliximab (GS-5745) (INN<ref name=WHOList115>World Health Organization,

 International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115, 
 WHO Drug Information, 
 2016,
 Vol. 30(Issue: 2),
 
 
 
 
 
 Full text,</ref>) is a humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

This drug was developed by Gilead Sciences, Inc.<ref>Statement On A Nonproprietary Name Adopted By The USAN Council - Andecaliximab, American Medical Association.</ref>

It is currently at Phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma.

References

<references/>

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

   This article is a medical stub. You can help WikiMD by expanding it!